SciVision Biotech Inc.

As of June 30, 2026, SciVision Biotech Inc. carries a market capitalization of 3.93B, placing it among publicly traded companies globally. Its enterprise value stands at 3.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

SciVision Biotech Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, SciVision Biotech Inc. has 73.17M shares outstanding.

As of June 30, 2026, SciVision Biotech Inc. trades at a trailing price-to-earnings ratio of 22.20. The price-to-sales ratio is 4.45, and the price-to-book ratio stands at 2.20.

As of June 30, 2026, SciVision Biotech Inc. trades at an EV/EBITDA multiple of 14.99 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.97 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. SciVision Biotech Inc. trades at an EV/FCF ratio of 55.97, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 3.51B versus a market cap of 3.93B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, SciVision Biotech Inc. maintains a current ratio of 6.46, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.17, indicating elevated leverage, while an interest coverage ratio of 19.82 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SciVision Biotech Inc. posted a return on equity (ROE) of 10.16, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.92 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.58, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.90, useful for judging operating efficiency across full business cycles. The company generates approximately 9.17M in revenue per employee across its workforce of 97.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.18 indicates how many times SciVision Biotech Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, SciVision Biotech Inc. recorded 29.25M in income tax expense. That works out to an effective tax rate of 14.11, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 207.36M, leaving 178.11M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, SciVision Biotech Inc.'s stock has declined approximately 57.77% over the past 52 weeks. The 50-day moving average sits at 44.89, while the 200-day moving average is 58.18.

Over the twelve months ended June 30, 2026, SciVision Biotech Inc. generated 889.15M in revenue and converted that into 178.11M in net income, yielding earnings per share of 2.31. EBITDA reached 234.07M, while operating income came in at 146.40M.

As of June 30, 2026, SciVision Biotech Inc. holds 905.67M in cash and equivalents against 485.61M in total debt, resulting in a net debt position of -299.24M. Total book value stands at 1.79B, with working capital of 1.10B providing operational flexibility.

SciVision Biotech Inc. produced 118.78M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -66.22M in capital expenditures, free cash flow totaled 52.56M - equivalent to 0.71 per share.

Over the twelve months ended June 30, 2026, SciVision Biotech Inc. posted a gross margin of 70.59, reflecting its pricing power and cost economics. The operating margin of 16.46 and net profit margin of 20.03 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, SciVision Biotech Inc. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.27, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -3.46, meaning SciVision Biotech Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

SciVision Biotech Inc.'s most recent stock split took place on October 4, 2021 with a 200:217 split ratio.

As of June 30, 2026, SciVision Biotech Inc. has an Altman Z-Score of 4.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.